Clinical trial
Randomized, Non-blinded Crossover Study to Establish the Bioequivalence Between Fixed Dose Combination (FDC) and Loose Combination of Acarbose and Metformin and to Investigate the Potential for a Drug-drug Interaction Following Single Oral Dosing in Healthy Adult Male Subjects
NCT01728740 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Non-blinded Crossover Study to Establish the Bioequivalence Between Fixed Dose Combination (FDC) and Loose Combination of Acarbose and Metformin and to Investigate the Potential for a Drug-drug Interaction Following Single Oral Dosing in Healthy Adult Male Subjects
- Lead sponsor
- Bayer
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2012
- Completion date
- December 31, 2012
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diabetes mellitus, type ii